PCPeer Christiansen

Peer Christiansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peer Christiansen has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence of concurrent severe self-reported late symptoms and functional limitations in cancer survivors: a cross-sectional study of sociodemographic, clinical, and lifestyle associations

    by Trille Kristina Kjaer, Anne Katrine Graudal Levinsen, Erik Jakobsen, Ismail Gögenur, Michael Borre, Peer Christiansen, Robert Zachariae, Peter Christensen, Peter de Nully Brown, Lisbet Rosenkrantz Hölmich, et al.

    This population-based study investigated the prevalence of concurrent severe symptoms and functional limitations among Danish cancer survivors, examining associations with sociodemographic, clinical, and lifestyle factors. We conducted a cross-sectional analysis using data from the nationwide SEQUEL questionnaire study (2022), including 40,766 survivors 2- to 12-year post-diagnosis (2010-2019). Up to 21 symptoms, five functioning domains, and sexual satisfaction were assessed using validated instruments (EORTC QLQ-C30, EORTC Item Library, QLQ-SHQ22, GAD-7, PHQ-9). Data were obtained from Danish registries, clinical databases, and self-report. Symptoms and functional limitations were categorized as severe using predefined thresholds. Ordinal logistic regression models examined factors associated with concurrent symptoms. Mean symptom count was 4.1 for women (range 0-21, SD 3.19) and 3.3 for men (range 0-20, SD 2.72), with 25% of women and 16% of men experiencing ≥ 5 concurrent severe symptoms. Lung cancer survivors reported the highest symptom burden. Factors significantly associated with concurrent symptoms included short education, lower income, living alone, multiple comorbidities (CCI ≥ 2), advanced disease, palliative treatment, current smoking, and higher BMI, with ORs ranging from 1.29-2.19 (women) and 1.23-2.25 (men). Impaired functioning showed similar associations. Concurrent late symptoms are common among cancer survivors, indicating complex health issues varying by cancer type and clinical characteristics, with clear socioeconomic disparities and lifestyle associations. These findings highlight subgroups who may benefit from interventions targeting multiple symptoms and underscore the importance of addressing social determinants and lifestyle factors in survivorship care.


  • Open Access

    The association between lymph node status and the tumor size in breast cancer – results from the Danish Breast Cancer Group (DBCG)

    by Tanja L. Fris, Marianne D. Lautrup, Peer M. Christiansen

    Background and purpose: The association between the tumor size and the risk of lymph node metastasis (LNM) is well known. The purpose of this study is to describe a new model for predicting the occurrence of LNM at an earlier time for breast cancer patients where at a given time this association is known. Patient/material and methods: The subjects studied were 59,400 breast cancer patients treated in the period 1995–2012 and registered in the Danish Breast Cancer Group (DBCG) database. Data included age, year of treatment, menopausal status, tumor size, lymph node status, localization, focality, histological type, grade, estrogen receptor (ER), HER2 status, lympho-vascular invasion (LVI), and type of surgery. Univariate and multivariate analyses were made. Results: 46% of patients presented with LNM. The occurrence increased with increasing tumor size. HER2 positive tumors had more LNM 56.9% versus 44.7% (p < 0.001) (odds ratio [OR] 1.17 [95% confidence interval, CI 1.09–1.26]) and mostly pronounced in relation to ER negative tumors (p < 0.001). ER negative/HER2 negative tumors had lower risk of LNM (OR 0.57 [95% CI 0.52–0.63]). Central tumors and tumors in the lower lateral quadrant were more often node positive. LVI showed increased odds for LNM (OR 5.16 [95% CI 4.84–5.52]). Interpretation: Increasing tumor size is the only time-dependent risk of LNM. HER2 positive tumors had an increased risk of LNM, and ER negative/HER2 negative tumors had a decreased risk of LNM. LVI was associated with substantial increased risk of LNM. The knowledge of breast cancer patient and tumor characteristics at a given time may predict stage of cancer at an earlier time.


  • Open Access

    Impact of postoperative complications and type 2 diabetes on breast cancer recurrence and mortality

    by Kasper A Kjærgaard, Peer Christiansen, Signe Borgquist, Deirdre Cronin-Fenton

    Background: Type 2 diabetes (T2D) is associated with increased risk of complications after breast cancer surgery. This study investigated systemic and surgical-site postoperative complications and the risk of early and late breast cancer recurrence and mortality, overall, and according to T2D status. Methods: From the Danish Breast Cancer Group (DBCG) and Danish registries, a cohort of women with incident early-stage breast cancer diagnosed 1996–2017 was assembled. All women underwent mastectomy or breast-conserving surgery. Using diagnostic codes, systemic and surgical-site complications within 30 days of surgery were defined. Early recurrence (<10 years from diagnosis) was ascertained from the DBCG and late recurrence (≥10 years after diagnosis) via a validated registry-based algorithm. Incidence rates (IRs) per 1000 person-years were calculated, and Cox regression was used to estimate adjusted hazard ratios (aHRs) of early and late recurrence, and death, according to postoperative complications. Potential effect measure modification by T2D was evaluated. Results: Among 58 198 women undergoing breast cancer surgery, 6285 (10.8%) had postoperative complications. Overall, 747 and 5756 women with and without complications developed early recurrence (IR: 19.7 and 17.9, aHR = 1.04, 95% c.i. 0.96, 1.13), whereas 314 and 3314 women developed late recurrence (IR: 23.9 and 26.0, and aHR = 0.90, 95% c.i. 0.80, 1.02). Prevalent T2D did not impact these findings. Women with postoperative complications had higher mortality rates than those without complications (aHR = 1.11; 95% c.i. 1.06, 1.16); especially those with T2D versus no T2D (aHR = 1.50; 95% c.i. 1.30, 1.73). Conclusion: Postoperative complications after breast cancer primary surgery did not impact recurrence risk but had a negative impact on survival, especially in women with T2D.


  • Impact of postoperative complications and type 2 diabetes on breast cancer recurrence and mortality

    by Kasper A Kjærgaard, Peer Christiansen, Signe Borgquist, Deirdre Cronin-Fenton

    Background: Type 2 diabetes (T2D) is associated with increased risk of complications after breast cancer surgery. This study investigated systemic and surgical-site postoperative complications and the risk of early and late breast cancer recurrence and mortality, overall, and according to T2D status. Methods: From the Danish Breast Cancer Group (DBCG) and Danish registries, a cohort of women with incident early-stage breast cancer diagnosed 1996–2017 was assembled. All women underwent mastectomy or breast-conserving surgery. Using diagnostic codes, systemic and surgical-site complications within 30 days of surgery were defined. Early recurrence (<10 years from diagnosis) was ascertained from the DBCG and late recurrence (≥10 years after diagnosis) via a validated registry-based algorithm. Incidence rates (IRs) per 1000 person-years were calculated, and Cox regression was used to estimate adjusted hazard ratios (aHRs) of early and late recurrence, and death, according to postoperative complications. Potential effect measure modification by T2D was evaluated. Results: Among 58 198 women undergoing breast cancer surgery, 6285 (10.8%) had postoperative complications. Overall, 747 and 5756 women with and without complications developed early recurrence (IR: 19.7 and 17.9, aHR = 1.04, 95% c.i. 0.96, 1.13), whereas 314 and 3314 women developed late recurrence (IR: 23.9 and 26.0, and aHR = 0.90, 95% c.i. 0.80, 1.02). Prevalent T2D did not impact these findings. Women with postoperative complications had higher mortality rates than those without complications (aHR = 1.11; 95% c.i. 1.06, 1.16); especially those with T2D versus no T2D (aHR = 1.50; 95% c.i. 1.30, 1.73). Conclusion: Postoperative complications after breast cancer primary surgery did not impact recurrence risk but had a negative impact on survival, especially in women with T2D.

  • Open Access

    Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo

    by Signe Borgquist, Maj-Britt Jensen, Cecilie Linea Bendorff, Peer Christiansen, Birgitte Vrou Offersen, Annette Raskov Kodahl, Marianne Ewertz, Anders Bonde Jensen, Thomas P Ahern, Deirdre Cronin-Fenton, et al.

    Purpose: Statin use has been consistently associated with improved clinical outcomes (especially recurrence) in breast cancer in multiple observational studies backed by compelling preclinical evidence. The strength of this evidence warrants a clinical trial to test the efficacy of statin exposure on breast cancer recurrence. Patients and Methods: The double-blind, phase III, randomized, placebo-controlled MASTER (MAmmary cancer STatins in ER positive breast cancer) trial includes women diagnosed with early-stage, estrogen receptor-positive (ER+) breast cancer who are candidates for systemic (neo)adjuvant therapy. Enrolled patients are given standard (neo)adjuvant therapy and additionally randomized to either atorvastatin (80 mg/day) or placebo for two years. The trial’s primary outcome is invasive disease-free survival (IDFS), with a target accrual of 3360 patients in total to achieve 80% power (two-sided alpha=0.05) to detect a 25% reduction in the risk of an IDFS event comparing the statin and placebo arms. At 3-, 6-, 12-, and 24-month follow-up time points, patients will have blood drawn for biomarker studies, answer patient-reported outcome (PRO) questionnaires, and control for adverse events. Subsequently, patients will receive annual PRO-criteria for Adverse Events (CTCAE) questionnaires until the completion of their 10 years of follow-up. Secondary endpoints include additional clinical endpoints; pathological response (neo-adjuvant treated patients), recurrence-free survival, distant-recurrence-free interval, overall survival and cardiac death-free interval, co-morbidity, and health-related quality-of-life measured by PRO-CTCAE questionnaires during and beyond study medication. Translational endpoints are evaluated in collected blood- and tumor samples. Discussion: If a protective effect of statins on breast cancer recurrence is supported by evidence from the MASTER trial, then the indications for a safe, well-tolerated, and inexpensive treatment can be expanded towards improved clinical outcomes for breast cancer patients.


  • Open Access

    Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups

    by J. B. Holm, E. Baggesen, D. Cronin-Fenton, J. Frystyk, J. M. Bruun, P. Christiansen, S. Borgquist

    Obesity and systemic inflammation are associated with breast cancer (BC) outcomes. Systemic inflammation is increased in obesity. We examined the association between C-reactive protein (CRP) and disease-free survival (DFS) and overall survival (OS) overall, and according to body mass index (BMI). We assembled a cohort of women with BC (stage I–III) seen at Aarhus University Hospital between 2010 and 2020 who donated blood at BC diagnosis (N = 2673). CRP levels were measured and divided into quartiles. We followed patients from surgery to recurrence, contralateral BC, other malignancy, death, emigration, or end-of-follow-up. We used Cox regression to estimate hazard ratios (HRs) with 95% confidence intervals (95% CIs) to compare outcomes across CRP quartiles, overall and stratified by BMI (normal-weight (18.5 ≤ BMI < 25 kg/m2), overweight (25 ≤ BMI < 30 kg/m2), and obesity (BMI ≥ 30 kg/m2)). During follow-up, 368 events (212 recurrences, 38 contralateral BCs, and 118 deaths) occurred (median follow-up 5.55 years). For DFS, high CRP (CRP ≥ 3.19 mg/L) was associated with an increased risk of events (HRadj:1.62 [95% CI = 1.14–2.28]). In BMI-stratified analyses, high CRP was associated with elevated risk of events in normal-weight and overweight (HRadj:1.70 [95% CI = 1.09–2.66]; HRadj:1.75 [95% CI = 1.08–2.86]), but in obesity, the estimate was less precise (HRadj:1.73 [95% CI = 0.78–3.83]). For OS, high CRP was associated with increased risk of death (HRadj:2.47 [95% CI = 1.62–3.76]). The association was strong in normal-weight and overweight (HRadj:3.66 [95% CI = 1.95–6.87]; HRadj:1.92 [95% CI = 1.06–3.46]), but less clear in obesity (HRadj:1.40 [95% CI = 0.64–3.09]). To sum up, high CRP levels at BC diagnosis were associated with inferior prognosis in early BC irrespective of BMI, although less clear in patients with obesity.


  • Top Cited Papers
    Open Access

    Interventions for insomnia in cancer patients and survivors—a comprehensive systematic review and meta-analysis

    by Eva Rames Nissen, Henrike Neumann, Sofie Møgelberg Knutzen, Emilie Nørholm Henriksen, Ali Amidi, Christoffer Johansen, Annika von Heymann, Peer Christiansen, Robert Zachariae

    Background: Considering the persistent nature and higher prevalence of insomnia in cancer patients and survivors compared with the general population, there is a need for effective management strategies. This systematic review and meta-analysis aimed to comprehensively evaluate the available evidence for the efficacy of pharmacological and nonpharmacological interventions for insomnia in adult cancer patients and survivors. Methods: Following the PRISMA guidelines, we analyzed data from 61 randomized controlled trials involving 6528 participants. Interventions included pharmacological, physical, and psychological treatments, with a focus on insomnia severity and secondary sleep and non-sleep outcomes. Frequentist and Bayesian analytical strategies were employed for data synthesis and interpretation. Results: Cognitive-Behavioral Therapy for Insomnia (CBT-I) emerged as the most efficacious intervention for reducing insomnia severity in cancer survivors and further demonstrated significant improvements in fatigue, depressive symptoms, and anxiety. CBT-I showed a large postintervention effect (g = 0.86; 95% confidence interval [CI] = 0.57 to 1.15) and a medium effect at follow-up (g = 0.55; 95% CI = 0.18 to 0.92). Other interventions such as bright white light therapy, sleep medication, melatonin, exercise, mind-body therapies, and mindfulness-based therapies showed benefits, but the evidence for their efficacy was less convincing compared with CBT-I. Brief Behavioral Therapy for Insomnia showed promise as a less burdensome alternative for patients in active cancer treatment. Conclusions: CBT-I is supported as a first-line treatment for insomnia in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes. The findings also highlight the potential of less intensive alternatives. The research contributes valuable insights for clinical practice and underscores the need for further exploration into the complexities of sleep disturbances in cancer patients and survivors.


  • Open Access

    Impact of type 2 diabetes on complications after primary breast cancer surgery: Danish population-based cohort study

    by Kasper Kjærgaard, Jannik Wheler, Looket Dihge, Peer Christiansen, Signe Borgquist, Deirdre Cronin-Fenton

    Background: Knowledge is sparse on the impact of type 2 diabetes (T2D) on surgical outcomes after breast cancer surgery. This study investigated the association between T2D and risk of complications after primary breast cancer surgery, and evaluated the biological interaction between T2D and co-morbidities. Methods: Using the Danish Breast Cancer Group clinical database, a cohort of all Danish women diagnosed with early-stage breast cancer during 1996–2022 was created. All patients underwent mastectomy or breast-conserving surgery. Information on prevalent T2D was collected from Danish medical and prescription registries. Surgical complications were defined as hospital diagnoses for medical or surgical complications developing within 30 days after primary breast cancer surgery. The 30-day cumulative incidence proportion of complications was calculated, and Cox regression was used to estimate HRs. Interaction contrasts were computed to determine the additive interaction between T2D and co-morbidities on the incidence rate of complications. Results: Among 98 589 women with breast cancer, 6332 (6.4%) had T2D at breast cancer surgery. Overall, 1038 (16.4%) and 9861 (10.7%) women with and without T2D developed surgical complications, yielding cumulative incidence proportions of 16 (95% c.i. 15 to 17) and 11 (10 to 11)% respectively, and a HR of 1.43 (95% c.i. 1.34 to 1.53). The incidence rate of surgical complications explained by the interaction of T2D with moderate and severe co-morbidity was 21 and 42%, respectively. Conclusion: Women with breast cancer and T2D had a higher risk of complications after primary breast cancer surgery than those without T2D. A synergistic effect of T2D and co-morbidity on surgical complications can explain this association.


  • Open Access

    Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer

    by Soojung Lee, Nicolai J. Toft, Trine V. Axelsen, Maria Sofia Espejo, Tina M. Pedersen, Marco Mele, Helene L. Pedersen, Eva Balling, Tonje Johansen, Mark Burton, et al.

    Background: Carbonic anhydrases catalyze CO2/HCO3– buffer reactions with implications for effective H+ mobility, pH dynamics, and cellular acid–base sensing. Yet, the integrated consequences of carbonic anhydrases for cancer and stromal cell functions, their interactions, and patient prognosis are not yet clear. Methods: We combine (a) bioinformatic analyses of human proteomic data and bulk and single-cell transcriptomic data coupled to clinicopathologic and prognostic information; (b) ex vivo experimental studies of gene expression in breast tissue based on quantitative reverse transcription and polymerase chain reactions, intracellular and extracellular pH recordings based on fluorescence confocal microscopy, and immunohistochemical protein identification in human and murine breast cancer biopsies; and (c) in vivo tumor size measurements, pH-sensitive microelectrode recordings, and microdialysis-based metabolite analyses in mice with experimentally induced breast carcinomas. Results: Carbonic anhydrases—particularly the extracellular isoforms CA4, CA6, CA9, CA12, and CA14—undergo potent expression changes during human and murine breast carcinogenesis. In patients with basal-like/triple-negative breast cancer, elevated expression of the extracellular carbonic anhydrases negatively predicts survival, whereas, surprisingly, the extracellular carbonic anhydrases positively predict patient survival in HER2/ErbB2-enriched breast cancer. Carbonic anhydrase inhibition attenuates cellular net acid extrusion and extracellular H+ elimination from diffusion-restricted to peripheral and well-perfused regions of human and murine breast cancer tissue. Supplied in vivo, the carbonic anhydrase inhibitor acetazolamide acidifies the microenvironment of ErbB2-induced murine breast carcinomas, limits tumor immune infiltration (CD3+ T cells, CD19+ B cells, F4/80+ macrophages), lowers inflammatory cytokine (Il1a, Il1b, Il6) and transcription factor (Nfkb1) expression, and accelerates tumor growth. Supporting the immunomodulatory influences of carbonic anhydrases, patient survival benefits associated with high extracellular carbonic anhydrase expression in HER2-enriched breast carcinomas depend on the tumor inflammatory profile. Acetazolamide lowers lactate levels in breast tissue and blood without influencing breast tumor perfusion, suggesting that carbonic anhydrase inhibition lowers fermentative glycolysis. Conclusions: We conclude that carbonic anhydrases (a) elevate pH in breast carcinomas by accelerating net H+ elimination from cancer cells and across the interstitial space and (b) raise immune infiltration and inflammation in ErbB2/HER2-driven breast carcinomas, restricting tumor growth and improving patient survival.


  • Prospective surveillance for breast cancer-related lymphedema (PROTECT)

    by Bolette Skjødt Rafn, Sandra Jensen, Eik Dybboe Bjerre, Merete Celano Wittenkamp, Kathrine Benjaminsen, Louise Pia Christensen, Henrik Flyger, Peer Christiansen, Christoffer Johansen

    Breast cancer-related lymphedema (BCRL) is a progressive condition caused by damage to the lymphatic system [1] and affects one in three patients following axillary lymph node dissection [2]. The e...